4.7 Article

Image-guided cancer therapy using aptamer-functionalized cross-linked magnetic-responsive Fe3O4@carbon nanoparticles

Journal

ANALYTICA CHIMICA ACTA
Volume 1056, Issue -, Pages 108-116

Publisher

ELSEVIER
DOI: 10.1016/j.aca.2018.12.045

Keywords

Theragnostic nanoparticles; Aptamer; Chemo-photothermal therapy; T-2-weighted; MR imaging

Funding

  1. Key Scientific Research Projects of Higher Education of Henan Province [18A430026]
  2. Jiangsu Six Category Outstanding Talent [2012-NY-031]
  3. Jiangsu Province Science and Technology Support Plan [BE2014327, BE2015367]
  4. Jiangsu Agricultural Science and Technology Innovation Fund [CX (15) 1016, JHB05-21]
  5. Priority Academic Program Development of Jiangsu Higher Education Institutions
  6. China Scholarship Council
  7. Nanjing-321
  8. Jiangsu Collaborative Innovation Center of Biomedical Functional Materials

Ask authors/readers for more resources

The excellent anticancer effect of combined differential cancer therapies has been observed in the last few decades. Efficient theragnostic nanoparticles (NPs) for malignancy treatment have received considerable research attention and widely investigated today. This study presents our results on the development of aptamer-functionalized Fe3O4@carbon@doxorubicin NPs (Apt-Fe3O4@C@DOX) and their application in the synergetic chemo-photothermal therapy (PTT) of cancer. The Apt-Fe3O4@C@DOX NPs displayed high photothermal conversion efficiency and extensive pH/heat-induced drug release. In vitro (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium) bromide experiments indicated that the combined chemo-PTT is much more toxic toward lung adenocarcinoma cells (A549) than PTT or chemotherapy alone. In addition, the Apt-Fe3O4@C@DOX NPs demonstrated decreasing contrast enhancement of magnetic resonance (MR) signals, which means they may be potentially applied as a contrast agent and serve as a critical component of T-2-weighted MR imaging of tumor tissues. Taking the results together, the Apt-Fe3O4@C@DOX NPs show great potential for cancer therapy. (C) 2018 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available